Site search
2831 results for '' found
A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory effi
A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory effi
/
Long-Term Outcomes of Lidocaine Infusions for Post-Operative Pain: the LOLIPOP Trial (NCT05072314)
Long-Term Outcomes of Lidocaine Infusions for Post-Operative Pain: the LOLIPOP Trial (NCT05072314)
/
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM302 in Combination with Toripalimab i
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM302 in Combination with Toripalimab i
/
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as
/
An Observational Multi center Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers [LIVER-R] (NCT06252753)
An Observational Multi center Study to Evaluate Real World Treatment Outcomes of Durvalumab based Regimens in Hepatobiliary Cancers [LIVER-R] (NCT06252753)
/
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept [MK-7962] Administered Using Either a Weight-based or Weight-banded Approach in
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept [MK-7962] Administered Using Either a Weight-based or Weight-banded Approach in
/
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acu
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acu
/
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Muta
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Muta
/
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias (NCT05756322)
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukaemias (NCT05756322)
/
Treatment of Locally Advanced NSCLC with Stereotactic ablativE Radiotherapy (LASER) (ACTRN12619001186145)
Treatment of Locally Advanced NSCLC with Stereotactic ablativE Radiotherapy (LASER) (ACTRN12619001186145)
/